Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for chronic rhinosinusitis with refractory nasal polyps
IRCT20181230042174N3Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Apr 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Baricitinib Group with Placebo Group (2 arms). Primary endpoints: Polyp size reduction, Rhinosinusitis symptom severity and 6 more. Started Apr 2025; status: completed.
02
Drugs
baricitinib
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on IRCT20181230042174N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181230042174N3.